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Wheezing in young children: WAITing for pharmacogenomics?
In The Lancet Respiratory Medicine, Chinedu Nwokoro 
and colleagues’1 WAIT trial assesses the eﬀ ectiveness of 
intermittent montelukast for treatment of wheezing 
episodes in 1358 children aged 10 months to 5 years 
who had had two or more wheeze episodes, with at 
least one episode in the preceding 3 months. There was 
no diﬀ erence in the primary outcome of unscheduled 
medical attendances for wheezing episodes between 
children in the montelukast and placebo groups 
(mean 2·0 [SD 2·6] vs 2·3 [2·7]; incidence rate ratio 
[IRR] 0·88, 95% CI 0·77–1·01; p=0·06). However, 
the subgroup of patients who carried the wild type 
(common) genotype of the 5-lipoxygenase (ALOX5) 
gene promoter, which encodes a key enzyme in the 
leukotriene synthesis pathway, had signiﬁ cantly 
reduced unscheduled severe medical attendances for 
wheezing episodes (2·0 [2·7] vs 2·4 [3·0]; IRR 0·80, 
95% CI 0·68–0·95; p=0·01). 
Prevention of wheeze episodes in children younger 
than 5 years has important beneﬁ t in terms of 
improvements in quality of life for children and their 
families, and reductions in health-care costs. However, 
an additional long-term beneﬁ t could be a change in the 
natural history of airway disease in these children.
Asthma begins in childhood,2 and wheezing 
episodes—a classic ﬁ nding in people with asthma—
generally happen in the ﬁ rst few years of life and 
are typically associated with viral respiratory-tract 
infections. These early wheezing episodes can have long-
term consequences. Children diagnosed with asthma at 
a young age have signiﬁ cantly impaired lung function3,4 
and at least one aspect of airway remodelling-increased 
thickness of the reticular basement membrane-
which seems to start as early as age 2–3 years5 and can 
be as severe in children of this age as it can in adult 
asthmatics.6 A model of airway inﬂ ammation suggests 
that airway remodelling is driven by both the frequency 
and severity of airway inﬂ ammatory events.7 In a follow-
up assessment of young adults from the Dunedin Birth 
Cohort, Sears and colleagues stated that “The challenge 
[in asthma] is to develop identiﬁ cation and treatment 
strategies applicable to early childhood that would 
reduce these adverse outcomes”.3
Could use of montelukast in children with the 
responsive ALOX5 genotype represent such an early 
intervention? The answer requires replication of the 
present study and additional long-term follow up 
studies, but the concept is exciting.  
Additional support for a salutory eﬀ ect of 
montelukast in the present study was provided by 
results of the secondary outcomes. In the entire 
study group, need for rescue oral corticosteroids was 
substantially decreased with 0·26 uses per child in 
the montelukast group versus 0·33 in the placebo 
group. This diﬀ erence between the active and placebo 
treatment groups was statistically signiﬁ cant (p=0·03) 
and clinically relevant, irrespective of the genotype. 
Additionally, time to ﬁ rst hospital admission was longer 
in children in the montelukast group than in those in 
the placebo group (p=0·04). 
Although the results are encouraging, they should 
be viewed with caution. The ﬁ ndings are concordant 
with some pharmacogenetic studies of the eﬀ ect of 
modifying response to leukotrienes, but discordant 
with others.8 Of perhaps greater concern is biological 
plausibility. Leukotriene E4 (LTE4), the urinary metabolite 
of cysteinyl leukotrienes, measured at recruitment was 
raised in carriers of the mutant genotype, showing 
no beneﬁ cial eﬀ ect from montelukast. This result is 
paradoxical. ALOX5 is in the promoter region of the 
gene and the wild-type gene variant functions as a 
more eﬀ ective promoter of gene expression and thus 
increases leukotriene production. This action suggests 
individuals with a more eﬀ ective promoter produce 
more leukotriene and are thus more responsive to 
its inhibition. A possible explanation is that LTE4 
was measured at baseline, whereas generation of 
leukotrienes during inﬂ ammatory events is what leads 
to wheezing episodes. Unfortunately, LTE4 was not 
measured during exacerbations.
Viral respiratory-tract infections are common, but 
no clinically useful approaches exist to decrease the 
prevalence of colds, which are the main trigger for 
wheezing episodes in children younger than 5 years. 
Therefore, if prevention of lifelong decrease in lung 
function is an aim, approaches to decrease the severity 
of wheezing episodes triggered by these infections 
should be considered.
Not all the children in this study will continue to 
wheeze. In the Tucson Children’s Respiratory Study, the 
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investigators developed a clinical index to deﬁ ne future 
asthma risk: the Asthma Predictive Index (API).9 The API 
was applied to children who had wheezing episodes by 
age 3 years to deﬁ ne those who would have persistent 
asthma by age 6 years. The scoring was positive with 
either one major risk factor (a parental history of 
asthma or physician diagnosed atopic dermatitis) 
or two of three minor risk factors (allergic rhinitis, 
eosinophilia, or wheezing without colds). Subsequent 
investigators have modiﬁ ed the original API, with 
removal of allergic rhinitis as a minor criterion and 
addition of allergic sensitisation either to aeroallergens 
as a major criterion, or to milk, egg, or peanut as a 
minor criterion.10
Nwokoro and colleagues refer to the Acute 
Intermittent Management Study (AIMS)11 and state that 
intermittent therapy showed no overall beneﬁ t in that 
study. That statement is correct for the trial’s primary 
outcome measure, which focused on the proportion of 
episode-free days during the 12 month trial in which 
the children were treated with intermittent leukotriene 
receptor antagonist (montelukast) or intermittent 
inhaled corticosteroid (budesonide) compared with 
placebo. However, intermittent treatment for 1 week 
with either montelukast or budesonide at the start of 
a wheezing episode produced a signiﬁ cant decrease in 
symptom severity, including less trouble breathing and 
less interference with activities, and the total symptom 
score. Of particular interest, in the modiﬁ ed API-positive 
group, there was even greater improvement for both 
trouble breathing and interference with activities that 
were reduced by 40–50% with intermittent treatment 
using either montelukast, or budesonide, compared 
with placebo. Furthermore, wheezing was signiﬁ cantly 
reduced by montelukast in the modiﬁ ed API-positive 
group.
Are we ready to begin genotyping high-risk children 
to institute a personalised prevention strategy for 
wheezing episodes? The frequency and severity of 
wheezing episodes in children younger than 5 years is 
an important burden for children, their families, and 
the health-care system. No gold-standard biological 
methods are presently available to diagnose asthma. 
Clinical scores are commonly used in primary care 
practices to predict risk for cardiovascular events, 
presence of dementia, and other health-care issues. 
These scores can help to direct diagnosis and treatment 
approaches. Genotyping is now standard practice in 
various clinical scenarios in which genotype might 
have an important eﬀ ect on diagnosis and treatment 
response. The costs of genotyping are decreasing 
rapidly and would be more than oﬀ set by savings 
in health-care use if the results from Nwokoro and 
colleagues’ study can be veriﬁ ed. We are almost there, 
and investigators have suggested that genomic 
sequencing might eventually become standard for 
screening of newborn babies.12 Before use of such 
genomic data for diagnostic and therapeutic purposes 
is considered, the validity of studies such as the WAIT 
trial should be conﬁ rmed.
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